News
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Two Big Law firms guided Merck & Co.'s plans to purchase respiratory drugmaker Verona Pharma Plc for around $10 billion.
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...
Barchart on MSN2d
What You Need To Know Ahead of Merck's Earnings ReleaseMerck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback